Lung Cancer
Volume 55, Issue 1 , Pages 25-34 , January 2007

Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms

  • Odilia Popanda

      Affiliations

    • Division of Toxicology and Cancer Risk Factors, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany
    • Corresponding Author InformationCorresponding author. Fax: +49 6221 42 3359.
    • ,
  • Lutz Edler

      Affiliations

    • Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
    • ,
  • Peter Waas

      Affiliations

    • Division of Toxicology and Cancer Risk Factors, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany
    • ,
  • Torsten Schattenberg

      Affiliations

    • Division of Toxicology and Cancer Risk Factors, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany
    • ,
  • Dorota Butkiewicz

      Affiliations

    • Department of Tumor Biology, Center of Oncology, M. Sklodowska-Curie Memorial Institute, Gliwice, Poland
    • ,
  • Thomas Muley

      Affiliations

    • Thoraxklinik am Universitätsklinikum Heidelberg, Germany
    • ,
  • Hendrik Dienemann

      Affiliations

    • Thoraxklinik am Universitätsklinikum Heidelberg, Germany
    • ,
  • Angela Risch

      Affiliations

    • Division of Toxicology and Cancer Risk Factors, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany
    • ,
  • Helmut Bartsch

      Affiliations

    • Division of Toxicology and Cancer Risk Factors, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany
    • ,
  • Peter Schmezer

      Affiliations

    • Division of Toxicology and Cancer Risk Factors, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany

Received 11 July 2006 ,Revised 7 September 2006 ,Accepted 14 September 2006.

References 

  1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–310
  2. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res. 2001;264:56–66
  3. Harada K, Ogden GR. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol. 2000;36:3–7
  4. Robles AI, Linke SP, Harris CC. The p53 network in lung carcinogenesis. Oncogene. 2002;21:6898–6907
  5. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol. 2001;28:3–13
  6. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J, Crawford LV. Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol. 1987;7:961–963
  7. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene. 2006;25:1602–1611
  8. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–1100
  9. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis. 2003;18:377–385
  10. Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol. 1997;26:14–23
  11. Devesa SS, Shaw GL, Blot WJ. Changing patterns of lung cancer incidence by histological type. Cancer Epidemiol Biomarkers Prev. 1991;1:29–34
  12. Butkiewicz D, Popanda O, Risch A, et al. Association between the risk for lung adenocarcinoma and a (-4) G-to-A polymorphism in the XPA gene. Cancer Epidemiol Biomarkers Prev. 2004;13:2242–2246
  13. Liu G, Miller DP, Zhou W, et al. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res. 2001;61:8718–8722
  14. Chedid M, Michieli P, Lengel C, Huppi K, Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene. 1994;9:3021–3024
  15. Shih CM, Lin PT, Wang HC, Huang WC, Wang YC. Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res. 2000;91:9–15
  16. Sjalander A, Birgander R, Rannug A, Alexandrie AK, Tornling G, Beckman G. Association between the p21 codon 31 A1 (arg) allele and lung cancer. Hum Hered. 1996;46:221–225
  17. Su L, Liu G, Zhou W, et al. No association between the p21 codon 31 serine–arginine polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2003;12:174–175
  18. Sun Y, Taeger D, Weiland SK, Keil U, Straif K. Job titles and work areas as surrogate indicators of occupational exposure. Epidemiology. 2003;14:361–367
  19. Boltze C, Roessner A, Landt O, Szibor R, Peters B, Schneider-Stock R. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol. 2002;21:1151–1154
  20. Tan XL, Popanda O, Ambrosone CB, et al. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res Treat. 2006;97:255–262
  21. Risch A, Dally H, Edler L. Genetic polymorphisms in metabolising enzymes as lung cancer risk factors. In:  Edler L,  Kitsos C editor. Recent Advances in Quantitative Methods in Cancer and Human Health Risk Assessment. John Wiley & Sons Ltd.; 2005;p. 43–62
  22. Breslow NE, Day NE. Statistical methods in cancer research. Volume I. The analysis of case–control studies. IARC Sci Publ. 1980;5–338
  23. McCullagh P. Regression models for ordinal data (with discussion). J R Stat Soc: B (Stat Meth) B. 1980;42:109–142
  24. Roh JW, Kim JW, Park NH, et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol. 2004;93:499–505
  25. Xi YG, Ding KY, Su XL, et al. p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis. 2004;25:2201–2206
  26. Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R, Runnebaum IB. p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res. 1998;18:2095–2099
  27. Birgander R, Sjalander A, Saha N, Spitsyn V, Beckman L, Beckman G. The codon 31 polymorphism of the p53-inducible gene p21 shows distinct differences between major ethnic groups. Hum Hered. 1996;46:148–154
  28. Fan R, Wu MT, Miller D, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:1037–1042
  29. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res. 2004;10:5845–5849
  30. Wu X, Zhao H, Amos CI, et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst. 2002;94:681–690
  31. Lai KC, Chen WC, Tsai FJ, Li SY, Jeng LB. Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. Hepatogastroenterology. 2005;52:944–948
  32. Chen YC, Xu L, Guo YL, et al. Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan: a preliminary study. Biomarkers. 2004;9:386–394
  33. Ohayon T, Gershoni-Baruch R, Papa MZ, Distelman MT, Eisenberg BS, Friedman E. The R72P P53 mutation is associated with familial breast cancer in Jewish women. Br J Cancer. 2005;92:1144–1148
  34. Dumont P, Leu JI, Della PA, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–365
  35. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004;108:196–199
  36. Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene. 2006;25:3489–3500
  37. Hu Y, McDermott MP, Ahrendt SA. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res. 2005;11:2502–2509
  38. Mechanic LE, Marrogi AJ, Welsh JA, et al. Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis. 2005;26:597–604
  39. Szymanowska A, Jassem E, Dziadziuszko R, et al. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer. 2006;52:9–14
  40. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle?. Biochim Biophys Acta. 2000;1471:M43–M56
  41. Su L, Sai Y, Fan R, et al. P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21. Lung Cancer. 2003;40:259–266
  42. Sakiyama T, Kohno T, Mimaki S, et al. Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer. 2005;114:730–737
  43. Barbone F, Bovenzi M, Cavallieri F, Stanta G. Cigarette smoking and histologic type of lung cancer in men. Chest. 1997;112:1474–1479
  44. Anderson GP, Bozinovski S. Acquired somatic mutations in the molecular pathogenesis of COPD. Trends Pharmacol Sci. 2003;24:71–76
  45. Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol. 1999;149:13–20
  46. Williams MD, Sandler AB. The epidemiology of lung cancer. Cancer Treat Res. 2001;105:31–52
  47. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513–1530
  48. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001;10:1239–1248

PII: S0169-5002(06)00485-5

doi: 10.1016/j.lungcan.2006.09.006

Lung Cancer
Volume 55, Issue 1 , Pages 25-34 , January 2007

Article Tools